Literature DB >> 15258755

A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile.

Paolo Monti1, Federica Marchesi, Michele Reni, Alessia Mercalli, Valeria Sordi, Alessandro Zerbi, Giampaolo Balzano, Valerio Di Carlo, Paola Allavena, Lorenzo Piemonti.   

Abstract

There are a large number of stable pancreatic ductal carcinoma cell lines (PDCL) that are used by researchers worldwide. Detailed data about their differentiation status and genetic alterations are present in the literature, but a systematic correlation with cell biological behavior is often lacking. PDCL ( n=12) were clustered by source of tumor cell (ascites, primary tumor, metastasis), and the data of functional cell biology were correlated with the reported structural and genetic profiles. Major histocompatibility complex expression, chemosensitivity and aneuploidia appeared to be related to the source of PDCL, and proliferative capacity appeared to be related to the grade of differentiation. No correlation between genetic/structural features of PDCL and biological behavior was found. All the cell lines appeared generally insensitive to in vitro treatment with 5-fluorouracil and showed variable degrees of susceptibility to gemcitabine, raltitrexed and oxaliplatin. All the PDCL showed resistance to Fas-mediated apoptosis but were significantly sensitive to the pro-apoptotic effect of inflammatory cytokines [interleukin (IL)-1beta, tumor necrosis factor (TNF)alpha and interferon gamma]. PDCL were characterized for the secretion of several factors relevant to the tumor-immune cross talk. Vascular endothelial growth factor, CCL2, CCL5 and transforming growth factor beta were the factors most frequently released; less frequent was the secretion of CXCL8, CCL22, IL-6 and sporadically CXCL12, IL-10 and hepatocyte growth factor. The cytokines IL-1beta and TNFalpha were always undetectable. In conclusion, a clear correlation between structural/genetic features and function could not be detected, suggesting the weakness of a "morphological" classification for the in vitro studies of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15258755     DOI: 10.1007/s00428-004-1053-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  65 in total

Review 1.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

2.  Adenovirus-mediated TNF-alpha gene transfer induces significant tumor regression in mice.

Authors:  P Wright; R Braun; L Babiuk; S D Littel-van den Hurk; T Moyana; C Zheng; Y Chen; J Xiang
Journal:  Cancer Biother Radiopharm       Date:  1999-02       Impact factor: 3.099

3.  Activation of the c-K-ras oncogene in a human pancreas carcinoma.

Authors:  H Hirai; T Okabe; Y Anraku; M Fujisawa; A Urabe; F Takaku
Journal:  Biochem Biophys Res Commun       Date:  1985-02-28       Impact factor: 3.575

4.  Ligation of the Fas antigen stimulates chemokine secretion in pancreatic cancer cell line PANC-1.

Authors:  M Shimada; A Andoh; Y Araki; Y Fujiyama; T Bamba
Journal:  J Gastroenterol Hepatol       Date:  2001-09       Impact factor: 4.029

Review 5.  Growth factors and their receptors in pancreatic cancer.

Authors:  F Ozawa; H Friess; A Tempia-Caliera; J Kleeff; M W Büchler
Journal:  Teratog Carcinog Mutagen       Date:  2001

6.  Fas and Fas-ligand expression in human pancreatic cancer.

Authors:  M Kornmann; T Ishiwata; J Kleeff; H G Beger; M Korc
Journal:  Ann Surg       Date:  2000-03       Impact factor: 12.969

7.  Immunological escape mechanisms in pancreatic carcinoma.

Authors:  H Ungefroren; M Voss; W V Bernstorff; A Schmid; B Kremer; H Kalthoff
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

8.  A new monoclonal antibody (5D3-F7) which recognizes human monocyte-chemotactic protein-1 but not related chemokines. Development of a sandwich ELISA and in situ detection of producing cells.

Authors:  G Peri; C Milanese; C Matteucci; L Ruco; D Zhou; S Sozzani; I Coletta; A Mantovani
Journal:  J Immunol Methods       Date:  1994-09-14       Impact factor: 2.303

9.  Histological and fine structural features of pancreatic ductal adenocarcinomas in relation to growth and prognosis: studies in xenografted tumours and clinico-histopathological correlation in a series of 75 cases.

Authors:  G Klöppel; G Lingenthal; M von Bülow; H F Kern
Journal:  Histopathology       Date:  1985-08       Impact factor: 5.087

10.  Differential localization of human pancreas cancer-associated antigen and carcinoembryonic antigen in homologous pancreatic tumoral xenograft.

Authors:  M H Tan; T Shimano; T M Chu
Journal:  J Natl Cancer Inst       Date:  1981-09       Impact factor: 13.506

View more
  24 in total

1.  Type I collagen and divalent cation shifts disrupt cell-cell adhesion, increase migration, and decrease PTHrP, IL-6, and IL-8 expression in pancreatic cancer cells.

Authors:  John J Grzesiak; Kathy C Smith; Cheryl Chalberg; Douglas W Burton; Leonard J Deftos; Michael Bouvet
Journal:  Int J Gastrointest Cancer       Date:  2005

2.  Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways.

Authors:  Nameeta Mujumdar; Tiffany N Mackenzie; Vikas Dudeja; Rohit Chugh; Mara B Antonoff; Daniel Borja-Cacho; Veena Sangwan; Rajinder Dawra; Selwyn M Vickers; Ashok K Saluja
Journal:  Gastroenterology       Date:  2010-04-29       Impact factor: 22.682

Review 3.  Animal Models: Challenges and Opportunities to Determine Optimal Experimental Models of Pancreatitis and Pancreatic Cancer.

Authors:  Jami L Saloman; Kathryn M Albers; Zobeida Cruz-Monserrate; Brian M Davis; Mouad Edderkaoui; Guido Eibl; Ariel Y Epouhe; Jeremy Y Gedeon; Fred S Gorelick; Paul J Grippo; Guy E Groblewski; Sohail Z Husain; Keane K Y Lai; Stephen J Pandol; Aliye Uc; Li Wen; David C Whitcomb
Journal:  Pancreas       Date:  2019-07       Impact factor: 3.327

4.  Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation.

Authors:  Paolo Piacentini; Massimo Donadelli; Chiara Costanzo; Patrick S Moore; Marta Palmieri; Aldo Scarpa
Journal:  Virchows Arch       Date:  2006-03-28       Impact factor: 4.064

Review 5.  Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.

Authors:  Ayesha Khalid; Joy Wolfram; Ilaria Ferrari; Chaofeng Mu; Junhua Mai; Zhizhou Yang; Yuliang Zhao; Mauro Ferrari; Xiaojing Ma; Haifa Shen
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

6.  MHC class II expression in pancreatic tumors: a link to intratumoral inflammation.

Authors:  Matthias M Gaida; Thilo Welsch; Esther Herpel; Darjus F Tschaharganeh; Lars Fischer; Peter Schirmacher; G Maria Hänsch; Frank Bergmann
Journal:  Virchows Arch       Date:  2011-11-27       Impact factor: 4.064

7.  A Biomimetic Tumor Model of Heterogeneous Invasion in Pancreatic Ductal Adenocarcinoma.

Authors:  Michael J Bradney; Stephanie M Venis; Yi Yang; Stephen F Konieczny; Bumsoo Han
Journal:  Small       Date:  2020-01-30       Impact factor: 13.281

Review 8.  Leukocytes as paracrine regulators of metastasis and determinants of organ-specific colonization.

Authors:  Neta Erez; Lisa M Coussens
Journal:  Int J Cancer       Date:  2011-03-25       Impact factor: 7.396

9.  Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.

Authors:  Sung Yong Oh; Hyun Jin Kim; Tae Hyo Kim; Gyeong-Won Lee; Hoon Gu Kim; Chi-Young Jeong; Hyuk-Chan Kwon; Jung Hun Kang
Journal:  Invest New Drugs       Date:  2009-05-15       Impact factor: 3.850

10.  Constitutive non-canonical NFkappaB signaling in pancreatic cancer cells.

Authors:  Catherine E Wharry; Kathleen M Haines; Richard G Carroll; Michael J May
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.